Coherus BioSciences Inc. (CHRS)
| Bid | 0.99 |
| Market Cap | 129.8M |
| Revenue (ttm) | 266.96M |
| Net Income (ttm) | 28.51M |
| EPS (ttm) | 0.28 |
| PE Ratio (ttm) | 4 |
| Forward PE | -1.11 |
| Analyst | Buy |
| Ask | 1.14 |
| Volume | 2,912,845 |
| Avg. Volume (20D) | 2,040,093 |
| Open | 1.02 |
| Previous Close | 1.01 |
| Day's Range | 1.01 - 1.14 |
| 52-Week Range | 0.66 - 2.43 |
| Beta | 1.01 |
About CHRS
Coherus BioSciences, Inc., a biopharmaceutical company, focuses on the biosimilar and immuno-oncology market primarily in the United States. The company markets UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte stimulating colony factor in the United States. Its pipeline products include biosimilars of Humira, Avastin, and Lucentis. The company also develops Toripalimab, a novel anti-PD-1 antibody for second-line treatment of melanoma ...
Analyst Forecast
According to 4 analyst ratings, the average rating for CHRS stock is "Buy." The 12-month stock price forecast is $7, which is an increase of 525.00% from the latest price.
Stock ForecastsNext Earnings Release
Analysts project revenue of ... Unlock content with Pro Subscription
1 month ago · seekingalpha.com
Coherus BioSciences, Inc. (CHRS) Q4 2024 Earnings Call TranscriptCoherus BioSciences, Inc. (NASDAQ:CHRS ) Q4 2024 Earnings Conference Call March 10, 2025 5:00 PM ET Company Participants Jodi Sievers - Head of IR Denny Lanfear - CEO Paul Reider - CCO Sameer Goregaok...